Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alfacell (ACEL) -- Ignore unavailable to you. Want to Upgrade?

To: Gil Kempenich who wrote (1346)	5/16/1998 8:42:00 PM
From: John Jenco	Read Replies (1) \| Respond to of 1533

I realize that the company is taking the moral high road by not promoting the stock, or as one person put it, by not playing the "me too" game, but I confess that I find something staggeringly amiss when I read this coming week's (May 18th) issue of TIME Magazine. As we anticipated, the cover story is... CANCER. The theme is "how to tell the hype from the hope". In the entire magazine, there is not one (as far as I could discern) reference to rnase technology, Onconase, or Alfacell. In fact, the author's put together an extensive chart beginning on p46 illustrating all 10 types of treatment therapy options, from traditional surgery to gene therapy, again with no mention of the rnase approach. Although many of the competitive drugs in use and under development were mentioned, Onconase was conspicuously absent (at least to me). Ditto for next week's issue fo U.S. News & World Report. Now, I can accept that someone may not believe in Onconase. I can also accept that writer's may have perhaps been turned off by the company's lack of helpfulness. BUT, I find myself at a complete loss to explain how a drug that seemingly performed quite well in FDA Phase II clinicals and is rumored to be repeating that performance with barely a month or two remaining in its Phase III trials... for pancreatic cancer... does not even rate a mention! Somebody please help me understand... Thanks. --John